Guest Editorial Patient navigation, financial toxicity top the agenda as Jill Biden, Kimryn Rathmell visit Atrium Health Wake Forest February 16, 2024Vol.50 No.07By Ruben A. Mesa
Guest Editorial SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing February 16, 2024Vol.50 No.07By Virginia Kaklamani, Srivani Ravoori and Carlos L. Arteaga
NCI Kimryn Rathmell: Flat funding in FY24 would mean more cuts to NCI programsNew NCI director to continue the National Cancer Plan set in motion by predecessor Monica Bertagnolli February 09, 2024Vol.50 No.06By Alexandria Carolan
Capitol Hill House committee issues subpoena for NIH’s Monica Bertagnolli to address NIH sexual misconduct policies February 09, 2024Vol.50 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter Shikha Jain, Shea Holman: It’s time for NIH to be transparent about how misconduct cases are handled February 09, 2024Vol.50 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024 February 09, 2024Vol.50 No.06By Paul Goldberg and Matthew Bin Han Ong
Trials & Tribulations Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry February 09, 2024Vol.50 No.06By Narjust Florez, Lauren Keil, Rebekah Kaufman and Oyepeju Abioye-Akintola
Impact factor mania and publish-or-perish may have contributed to Dana-Farber retractions, experts sayLearning from past errors (and misconduct) in cancer research February 02, 2024Vol.50 No.05By Jacquelyn Cobb
Regulatory News FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies February 02, 2024Vol.50 No.05By Alexandria Carolan
